Kite On Track to Launch First CAR-T Drug in 2017; Shares Fairly Valued
We do not plan on changing our $65 per share fair value estimate, as lead candidate KTE-C19’s development timeline continues to track our model expectations. Kite has the most advanced chimeric antigen receptor T-cell, or CAR-T, therapy in development, even more so since Juno’s CAR-T candidate was temporarily halted as a result of several patient deaths in July 2016. Kite could stake out a promising footing in the novel immunotherapy market, should KTE-C19 successfully gain approval. While we aw...
Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.
Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.
We have operations in 27 countries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.